In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Myriad Genetics, Inc. (NASDAQ: MYGN) closed at $27.61 in the last session, down -2.02% from day before closing price of $28.18. In other words, the price has decreased by -$2.02 from its previous closing price. On the day, 0.47 million shares were traded. MYGN stock price reached its highest trading level at $28.3 during the session, while it also had its lowest trading level at $27.61.
Ratios:
We take a closer look at MYGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.96. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on June 27, 2024, initiated with a Sector Outperform rating and assigned the stock a target price of $29.
Leerink Partners Upgraded its Market Perform to Outperform on May 08, 2024, whereas the target price for the stock was revised from $25 to $35.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 04 ’24 when SPIEGELMAN DANIEL K sold 3,788 shares for $22.05 per share. The transaction valued at 83,525 led to the insider holds 32,917 shares of the business.
SPIEGELMAN DANIEL K sold 3,788 shares of MYGN for $83,488 on Jun 03 ’24. The Director now owns 36,705 shares after completing the transaction at $22.04 per share. On May 14 ’24, another insider, DIAZ PAUL J, who serves as the President and CEO of the company, sold 95,000 shares for $25.21 each. As a result, the insider received 2,394,798 and left with 1,141,166 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 2507551232 and an Enterprise Value of 2553550080. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 3.39. Its current Enterprise Value per Revenue stands at 3.183 whereas that against EBITDA is -52.113.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $28.90, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 8.52%, while the 200-Day Moving Average is calculated to be 27.29%.
Shares Statistics:
According to the various share statistics, MYGN traded on average about 815.87K shares per day over the past 3-months and 865130 shares per day over the past 10 days. A total of 89.90M shares are outstanding, with a floating share count of 87.08M. Insiders hold about 4.12% of the company’s shares, while institutions hold 105.38% stake in the company. Shares short for MYGN as of 1722384000 were 4389034 with a Short Ratio of 5.38, compared to 1719532800 on 4612718. Therefore, it implies a Short% of Shares Outstanding of 4389034 and a Short% of Float of 6.760000400000001.
